Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. Stock
We can see a decrease in the price for Ocuphire Pharma Inc.. Compared to yesterday it has lost -€0.080 (-2.520%).
Our community identified positive and negative aspects for Ocuphire Pharma Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocuphire Pharma Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc. | -2.520% | -4.762% | -7.514% | 223.559% | 90.250% | -13.978% | -17.098% |
| Actinium Pharmaceuticals Inc. | -9.090% | 37.101% | 17.370% | -36.210% | -21.624% | -83.548% | -82.318% |
| NanoViricides Inc. | 0.000% | -1.709% | -24.342% | -11.538% | 23.656% | -0.862% | -62.121% |
| AnaptysBio Inc | -1.840% | 2.661% | 0.672% | 199.529% | 18.419% | 184.469% | 135.741% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
